For those of us still following the progress of Cavatak, Merck is presenting the results of the KEYNOTE 200 trial at ESMO18 on the 20th Oct.
LBA40 - Phase 1b KEYNOTE-200. A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients
Presentation Number LBA40
Lecture Time17:15 - 17:15
Speakers Charles M. Rudin (New York, US)
http://212.114.167.162/slidecenter/esmo2018/attendee/confcal/session/calendar?q=lba40
- Forums
- ASX - By Stock
- what is merck doing with cavatac
For those of us still following the progress of Cavatak, Merck...
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online